ES2556468T3 - Mutaciones en el gen del receptor del factor de crecimiento epidérmico - Google Patents
Mutaciones en el gen del receptor del factor de crecimiento epidérmico Download PDFInfo
- Publication number
- ES2556468T3 ES2556468T3 ES12745460.1T ES12745460T ES2556468T3 ES 2556468 T3 ES2556468 T3 ES 2556468T3 ES 12745460 T ES12745460 T ES 12745460T ES 2556468 T3 ES2556468 T3 ES 2556468T3
- Authority
- ES
- Spain
- Prior art keywords
- egfr
- cetuximab
- mutant
- cells
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382270A EP2554551A1 (en) | 2011-08-03 | 2011-08-03 | Mutations in the epidermal growth factor receptor gene |
| EP11382270 | 2011-08-03 | ||
| PCT/EP2012/065090 WO2013017645A1 (en) | 2011-08-03 | 2012-08-02 | Mutations in the epidermal growth factor receptor gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2556468T3 true ES2556468T3 (es) | 2016-01-18 |
Family
ID=46640020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12745460.1T Active ES2556468T3 (es) | 2011-08-03 | 2012-08-02 | Mutaciones en el gen del receptor del factor de crecimiento epidérmico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9765399B2 (https=) |
| EP (3) | EP2554551A1 (https=) |
| JP (1) | JP6149034B2 (https=) |
| KR (1) | KR20140072035A (https=) |
| CN (1) | CN103717616B (https=) |
| AU (1) | AU2012292024A1 (https=) |
| BR (1) | BR112014002373A2 (https=) |
| CA (1) | CA2842270C (https=) |
| ES (1) | ES2556468T3 (https=) |
| IN (1) | IN2014CN00570A (https=) |
| RU (1) | RU2014107908A (https=) |
| WO (1) | WO2013017645A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| EP3805404A1 (en) | 2014-05-13 | 2021-04-14 | Board of Regents, The University of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| US11015225B2 (en) * | 2014-07-28 | 2021-05-25 | Alberto Bardelli | Method of treating cancer based on identifying mutations in the extracellular domain III of epidermal growth factor receptor gene |
| CN104531854B (zh) * | 2014-11-10 | 2017-01-18 | 中国人民解放军第三〇七医院 | 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒 |
| WO2016172584A1 (en) * | 2015-04-24 | 2016-10-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
| RU2626682C1 (ru) * | 2016-07-20 | 2017-07-31 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта |
| CN111499749B (zh) * | 2020-03-13 | 2021-11-09 | 浙江大学 | 一种西妥昔单抗突变体及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070275386A1 (en) | 2004-03-01 | 2007-11-29 | Ratain Mark J | Polymorphisms in the Epidermal Growth Factor Receptor Gene Promoter |
| TW200533339A (en) | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| WO2006009694A2 (en) * | 2004-06-14 | 2006-01-26 | Imclone Sysetms Incorporated | Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof |
| MX2007009963A (es) * | 2005-02-24 | 2007-09-26 | Amgen Inc | Mutaciones del receptor del factor de crecimiento epidermico. |
| CN1737162A (zh) * | 2005-03-16 | 2006-02-22 | 南京中医药大学附属医院(江苏省中医院) | 表皮生长因子受体(egfr)基因测序检测方法 |
| US7981606B2 (en) * | 2005-12-21 | 2011-07-19 | Roche Molecular Systems, Inc. | Control for nucleic acid testing |
| AU2007329740B2 (en) * | 2006-10-26 | 2014-05-01 | Genentech, Inc. | Genetic variations associated with tumors |
| WO2008088860A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphisms in the egfr pathway as markers for cancer treatment |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| US8137919B2 (en) * | 2008-04-10 | 2012-03-20 | Montefiore Medical Center | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib |
| US8583380B2 (en) * | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
-
2011
- 2011-08-03 EP EP11382270A patent/EP2554551A1/en not_active Withdrawn
-
2012
- 2012-08-02 JP JP2014523328A patent/JP6149034B2/ja active Active
- 2012-08-02 BR BR112014002373A patent/BR112014002373A2/pt not_active Application Discontinuation
- 2012-08-02 CN CN201280037669.7A patent/CN103717616B/zh active Active
- 2012-08-02 CA CA2842270A patent/CA2842270C/en active Active
- 2012-08-02 WO PCT/EP2012/065090 patent/WO2013017645A1/en not_active Ceased
- 2012-08-02 RU RU2014107908/10A patent/RU2014107908A/ru not_active Application Discontinuation
- 2012-08-02 ES ES12745460.1T patent/ES2556468T3/es active Active
- 2012-08-02 EP EP12745460.1A patent/EP2739648B1/en active Active
- 2012-08-02 EP EP15184046.9A patent/EP2995623A1/en not_active Withdrawn
- 2012-08-02 IN IN570CHN2014 patent/IN2014CN00570A/en unknown
- 2012-08-02 KR KR1020147005437A patent/KR20140072035A/ko not_active Withdrawn
- 2012-08-02 AU AU2012292024A patent/AU2012292024A1/en not_active Abandoned
- 2012-08-02 US US14/236,614 patent/US9765399B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2739648A1 (en) | 2014-06-11 |
| KR20140072035A (ko) | 2014-06-12 |
| RU2014107908A (ru) | 2015-09-10 |
| CA2842270C (en) | 2019-10-29 |
| JP6149034B2 (ja) | 2017-06-14 |
| BR112014002373A2 (pt) | 2017-02-21 |
| CN103717616B (zh) | 2016-06-29 |
| US20140170662A1 (en) | 2014-06-19 |
| CN103717616A (zh) | 2014-04-09 |
| EP2739648B1 (en) | 2015-09-16 |
| JP2014521342A (ja) | 2014-08-28 |
| AU2012292024A1 (en) | 2014-02-27 |
| WO2013017645A1 (en) | 2013-02-07 |
| IN2014CN00570A (https=) | 2015-04-03 |
| EP2554551A1 (en) | 2013-02-06 |
| EP2995623A1 (en) | 2016-03-16 |
| CA2842270A1 (en) | 2013-02-07 |
| US9765399B2 (en) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2556468T3 (es) | Mutaciones en el gen del receptor del factor de crecimiento epidérmico | |
| ES2663556T3 (es) | Anticuerpos frente al receptor alfa del folato y usos de los mismos | |
| ES2661238T3 (es) | Biomarcadores y métodos para determinar la eficacia de anticuerpos anti-EGFR en la terapia del cáncer | |
| ES2687783T3 (es) | Biomarcadores de cáncer y usos de los mismos | |
| ES2540802T3 (es) | Proteínas de unión específica y uso de las mismas | |
| ES2753360T3 (es) | Anticuerpos contra PD-L1 y usos de los mismos | |
| ES2833962T3 (es) | Respuesta antitumoral a epítopos propios modificados | |
| US20160245812A1 (en) | Tumor cell-derived microvesicles | |
| ES2894323T3 (es) | Sistema y productos para una mejor cuantificación de la actividad ADCC | |
| JP7279026B2 (ja) | Ｎａｐｉ２ｂ標的化療法に対する応答を予測するための組成物および方法 | |
| ES2523992T3 (es) | La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo | |
| HRP20100412T1 (hr) | Identifikacija površinskih antigena radi dijagnoze i liječenja tumora | |
| CN114127115A (zh) | 结合CLEC12a的多肽及其用途 | |
| Hasegawa et al. | Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor | |
| ES2901602T3 (es) | Composiciones y métodos para detectar y tratar el cáncer ovárico | |
| ES2670588T3 (es) | Péptidos derivados de soricidina y métodos para la detección de cánceres TRPV-6 y administración de fármacos | |
| WO2016136372A1 (ja) | Ｃｋａｐ４を標的分子とした抗腫瘍剤 | |
| JP2017526916A (ja) | 癌の診断 | |
| Kim et al. | Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2) | |
| JPWO2019065747A1 (ja) | 抗ｃｋａｐ４モノクローナル抗体 | |
| ES2899360T3 (es) | Composiciones y procedimientos para detectar y tratar cáncer gástrico | |
| Rathore et al. | Liver endothelium microenvironment promotes HER3-mediated cell growth in pancreatic ductal adenocarcinoma | |
| Hu et al. | Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis | |
| ES2382987T3 (es) | Método de detección de cáncer de hígado, diagnóstico de cáncer de hígado y curación del cáncer | |
| Nelson et al. | An increasingly important therapeutic target: Part 2 Distribution of HER2/neu Overexpression and Gene Amplification by Organ, Tumor Site and Histology |